2-氯苯并噻唑-6-甲酸乙酯 | 78485-37-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻唑类
• 中文名称: 2-氯苯并噻唑-6-甲酸乙酯
• 中文别名: 2-氯-1,3-苯并噻唑-6-甲酸乙酯；2-氯苯并噻唑-6-羧酸乙酯
• 英文名称: ethyl 2-chlorobenzo[d]thiazole-6-carboxylate
• 英文别名: ethyl-2-chlorobenzothiazole-6-carboxylate；Ethyl 2-chloro-6-benzothiazolecarboxylate；ethyl 2-chloro-1,3-benzothiazole-6-carboxylate
• CAS: 78485-37-7
• 化学式: C₁₀H₈ClNO₂S
• mdl: MFCD08443995
• 分子量: 241.698
• InChiKey: XISSCVMIXDMKLH-UHFFFAOYSA-N

物化性质

• 熔点：
  90-92°
• 沸点：
  340.5±15.0 °C(Predicted)
• 密度：
  1.400

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  67.4
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2934999090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Ethyl 2-chloro-6-benzothiazolecarboxylate
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Ethyl 2-chloro-6-benzothiazolecarboxylate
CAS number: 78485-37-7

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C10H8ClNO2S
Molecular weight: 241.7

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride, sulfur oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-氯苯并噻唑-6-甲酸乙酯 在 lithium hydroxide monohydrate 、 水 、 三乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 85.0h， 生成 (S)-2-methyl-2-(2-((2-methyl-3-((5-(methylthio)pyrimidin-2-yl)amino)propyl)amino)benzo[d]thiazole-6-carboxamido)propanoic acid
  参考文献：
  名称：

  WO2020150474A5

  摘要：

  公开号：

  WO2020150474A5
• 作为产物：
  描述：

  2-氨基苯并噻唑-6-羧酸乙酯 在 亚硝酸特丁酯 、 copper dichloride 作用下， 以 乙腈 为溶剂， 以80.9 %的产率得到2-氯苯并噻唑-6-甲酸乙酯
  参考文献：
  名称：

  一种苯并噻唑类化合物、制备方法和用途

  摘要：

  本发明公开了一种苯并噻唑类化合物、制备方法和用途。本发明提供了系列苯并噻唑类化合物，活性研究表明该苯并噻唑类化合物对PCSK9均具有较好的抑制作用，可以用于开发制备PCSK9抑制剂药物，用于制备治疗通过阻断PCSK9而得到治疗或缓解的疾病的药物，比如高胆固醇血症。

  公开号：

  CN115109011A

文献信息

• FXR RECEPTOR MODULATOR, PREPARATION METHOD THEREFOR, AND USES THEREOF
  申请人：Guangzhou Henovcom Bioscience Co. Ltd.

  公开号：EP3401315A1

  公开（公告）日：2018-11-14

  The present disclosure disclosed a modulator of FXR receptor and preparation and use thereof, which relates to the technical filed of medicinal chemistry. The present disclosure provides a modulator of FXR receptor having a structural formula I or a pharmaceutically acceptable salt, stereoisomer, solvate or prodrug thereof, which can combine with FXR receptor (that is NR1H4) and be acted as a FXR agonist or a partial agonist for preventing and treating the disease mediated by FXR, such as chronic intrahepatic or extrahepatic cholestasis, hepatic fibrosis caused by chronic cholestasis or acute intrahepatic cholestasis, chronic hepatitis B, gallstone, hepatic carcinoma, colon cancer or intestinal inflammatory disease, etc. Specifically, for some chemical compounds, their EC50 for FXR agonist activity reach below 100nM, which show an excellent FXR agonist activity and an excellent prospect to provide a new pharmaceutical selection in clinical treatment for the disease mediated by FXR.

  本公开揭示了一种FXR受体调节剂及其制备和使用，涉及药物化学技术领域。本公开提供了一种具有结构式I或其药用可接受盐、立体异构体、溶剂合物或前药的FXR受体调节剂，可与FXR受体（即NR1H4）结合，并作为FXR激动剂或部分激动剂用于预防和治疗由FXR介导的疾病，如慢性肝内或肝外胆汁淤积、慢性胆汁淤积或急性肝内胆汁淤积引起的肝纤维化、慢性乙型肝炎、胆结石、肝癌、结肠癌或肠道炎症性疾病等。具体而言，对于某些化合物，它们的FXR激动剂活性的EC50值低于100nM，表现出优异的FXR激动剂活性，并有望为由FXR介导的疾病在临床治疗中提供新的药物选择。
• [EN] ANTIVIRAL HETEROCYCLIC COMPOUNDS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES ANTIVIRAUX
  申请人：ENANTA PHARM INC

  公开号：WO2021066922A1

  公开（公告）日：2021-04-08

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HRSV or HMPV infection. The invention also relates to methods of treating an HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明公开了化合物的结构式（I），或其药学上可接受的盐、酯或前药：这些化合物抑制人类呼吸道合胞病毒（HRSV）或人类甲型流感病毒（HMPV）的抑制剂。本发明还涉及包含上述化合物的药物组合物，用于治疗患有HRSV或HMPV感染的受试者。该发明还涉及通过给予含有本发明化合物的药物组合物来治疗受试者的HRSV或HMPV感染的方法。
• [EN] COMPOSITIONS AND METHODS FOR MODULATING FXR<br/>[FR] COMPOSITIONS ET PROCÉDÉS POUR LA MODULATION DE FXR
  申请人：IRM LLC

  公开号：WO2012087519A1

  公开（公告）日：2012-06-28

  The present invention relates to compounds of Formula (I), a stereoisomer, enantiomer, a pharmaceutically acceptable salt or an amino acid conjugate thereof; wherein variables are as defined herein; and their pharmaceutical compositions, which are useful as modulators of the activity of Farnesiod X receptors (FXR).

  本发明涉及式(I)的化合物，其立体异构体、对映体、药学上可接受的盐或氨基酸结合物；其中变量如本文所定义；以及它们的药物组合物，其作为法尼索德X受体（FXR）活性调节剂而有用。
• Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH)
  作者：David C. Tully、Paul V. Rucker、Donatella Chianelli、Jennifer Williams、Agnès Vidal、Phil B. Alper、Daniel Mutnick、Badry Bursulaya、James Schmeits、Xiangdong Wu、Dingjiu Bao、Jocelyn Zoll、Young Kim、Todd Groessl、Peter McNamara、H. Martin Seidel、Valentina Molteni、Bo Liu、Andrew Phimister、Sean B. Joseph、Bryan Laffitte

  DOI：10.1021/acs.jmedchem.7b00907

  日期：2017.12.28

  non-bile acid FXR agonists that introduce a bicyclic nortropine-substituted benzothiazole carboxylic acid moiety onto a trisubstituted isoxazole scaffold. Herein, we report the discovery of 1 (tropifexor, LJN452), a novel and highly potent agonist of FXR. Potent in vivo activity was demonstrated in rodent PD models by measuring the induction of FXR target genes in various tissues. Tropifexor has advanced

  法尼醇X受体（FXR）是一种核受体，可作为胆汁酸代谢和信号转导的主要调节剂。FXR的激活抑制胆汁酸的合成并增加胆汁酸的结合，转运和排泄，从而保护肝脏免受胆​​汁积聚的有害影响，从而导致人们对FXR作为治疗胆汁淤积和非酒精性脂肪性肝炎的治疗靶标产生了浓厚的兴趣。我们确定了一系列新型的强效非胆汁酸FXR激动剂，该激动剂可将双环的奥氮平取代的苯并噻唑羧酸部分引入三取代的异恶唑支架上。在此，我们报告1的发现（tropifexor，LJN452），一种新型且高效的FXR激动剂。通过测量各种组织中FXR靶基因的诱导，在啮齿类动物PD模型中证明了体内活性很强。Tropifexor已进入NASH和PBC患者的2期人类临床试验。
• Water-Promoted Chlorination of 2-Mercaptobenzothiazoles
  作者：Laurin Wimmer、Michael Parmentier、Bernard Riss、Tobias Kapferer、Chao Ye、Lei Li、Hongyong Kim、Jialiang Li

  DOI：10.1055/s-0036-1591553

  日期：2018.5

  Substituted benzothiazoles play an important role in medicinal chemistry due to their pharmacological properties. Their 2-substituted derivatives are often prepared from 2-chlorobenzothiazoles, which in turn can be synthesized from the 2-mercapto precursor using sulfuryl chloride. In practice, this seemingly straightforward and widely used reaction can be impeded by poor reproducibility and low reaction yields

  摘要 取代的苯并噻唑由于其药理特性，在药物化学中起着重要作用。它们的2-取代衍生物通常由2-氯苯并噻唑制备，而后者又可以使用硫酰氯由2-巯基前体合成。在实践中，这种看似直接和广泛使用的反应可能会因重现性差和反应产率低而受到阻碍。在此交流中，我们报告说，将水简单添加到反应中会显着提高反应效率。我们将此效应归因于通过磺酰氯的部分水解而形成酸。该假设得到以下观察结果的支持：在一些无水酸性添加剂的存在下，收率也得到了提高。 取代的苯并噻唑由于其药理特性，在药物化学中起着重要作用。它们的2-取代衍生物通常由2-氯苯并噻唑制备，而后者又可以使用硫酰氯由2-巯基前体合成。在实践中，这种看似直接和广泛使用的反应可能会因重现性差和反应产率低而受到阻碍。在此交流中，我们报告说，将水简单添加到反应中会显着提高反应效率。我们将此效应归因于通过磺酰氯的部分水解而形成酸。该假设得到以下观察结果的支持：在一些无水酸性添加剂的存在下，收率也得到了提高。